Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UC7-13D5 is a **monoclonal antibody** derived from Armenian hamster that specifically binds to the **murine gamma/delta T cell receptor (TCR γ/δ)**. It is primarily utilized in experimental immunology to identify, deplete, or functionally block mouse γδ T cells both in vitro and in vivo. The γδ TCR is expressed by a subset of T cells in the thymus, peripheral lymphoid tissues, and various epithelial surfaces. UC7-13D5 can activate TCR γ/δ-bearing cells in vitro and has been reported to cause depletion or functional blocking of these cells in vivo. The mechanism involves binding to the TCR γ/δ, leading to downregulation or internalization of the receptor, thus making the γδ T cells "invisible" to some detection methods but not fully depleted. The antibody is widely used as a reagent in research to study the roles of γδ T cells in immunity, infection, autoimmunity, and cancer models[1][2][4][5][7][9][10][12][16].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UC7-13D5.